ArticlePlanta2026
Voacangine/coronaridine hydroxylases catalyze C19-hydroxylation in iboga alkaloid synthesis.
Article in Planta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification and Optimization of Kratom Strictosidine Pathway Enabled by Yeast Multiplex Engineering.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
MAIN
conclusionThe combination of bioinformatics and functional approaches was used to identify three cytochrome P450 from the CYP71 clan that perform the 19-hydroxylation of two monoterpene indole alkaloids (coronaridine and voacangine) from Voacanga thouarsii. Voacanga thouarsii is a medicinal plant from the Apocynaceae family producing monoterpene indole alkaloids (MIAs), notably iboga-type ones, to cope with their environment. Iboga MIAs, including ibogaine or voacristine, display a wide range of pharmacological properties explaining the ever-growing interest in these compounds. Although much of the iboga biosynthetic pathway has been resolved, the enzymes responsible for the C19-hydroxylation of coronaridine and voacangine, which leads to heyneanine and voacristine, remain unknown. Using newly available genomic and transcriptomic resources, we performed an orthology-guided strategy to identify candidate cytochrome P450 enzymes from the CYP71 family. Functional characterization through transient expression in Nicotiana benthamiana revealed three closely related enzymes capable of stereospecific C19-hydroxylation of both substrates. These enzymes, named voacangine/coronaridine hydroxylases (VCOH1-3), display moderate substrate specificity and a preferential activity toward coronaridine. Subcellular localization confirmed their association with the endoplasmic reticulum, consistent with other MIA-related P450s. Homology modeling and molecular docking analyses identified key residues that constrain substrate orientation and explain the observed stereochemical outcome of hydroxylation. Together, these findings complete the biosynthetic pathways of voacristine and heyneanine and highlight convergent evolutionary solutions for C19-hydroxylation within MIAs. By identifying and mechanistically characterizing the enzymes responsible for this missing biosynthetic step, this work significantly advances the state of the art in iboga MIA biosynthesis and provides new molecular tools for their metabolic engineering and the sustainable production of these valuable compounds.
Indexed as
Identifiers
41870636What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.